Theorem Clinical Research Inc Troy, NY - 12180

Theorem Clinical Research Inc is categorized under Research and Development Laboratories in Troy, NY .

Theorem Clinical Research Inc was established in 0, and today employs 1 to 4, earning Unknown per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.

If you are seeking more information, feel free to contact Ronald Weishaar at the company’s branch by writing to 185 Jordan Road # 1, Troy, New York NY 12180 or by phoning (518) 283-4000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Theorem Clinical Research Inc
Contact Person: Ronald Weishaar
Address: 185 Jordan Road # 1, Troy, New York 12180
Phone Number: (518) 283-4000
Website Address: theoremclinical.com
Annual Revenue (USD): Unknown
Location Type: Branch
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Research and Development Laboratories
SIC Code: 8731
NAICS Code: 541712
Share This Business:

Theorem Clinical Research Inc was started in 0 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.

Feel free to contact Ronald Weishaar for inquiries that concern Theorem Clinical Research Inc by calling the company number (518) 283-4000, as your correspondence is most welcome. Additionally, the physical location of the branch of Theorem Clinical Research Inc can be found at the coordinates 42.678015,-73.695609 as well as the street address 185 Jordan Road # 1 in Troy, New York 12180.

For its online presence, you may visit Theorem Clinical Research Inc’s website at theoremclinical.com and engage with its social media outlets through on Twitter and on Facebook.